Kalaris Therapeutics, Inc. Insider Trading
KLRS
Insiders sold 13K and bought nothing on the open market.
None of the selling was scheduled in advance under a 10b5-1 plan. Chief Accounting Officer Brett R Hagen sold 13K on Mar 20, 100% of their stake, outside a plan. The last open-market buy by an executive or director was in Apr 2022.
Get an email when KLRS's executives or directors buy, or make a large sale outside a plan.
Trades · last 2 years
| Date | Insider | Trade | Shares | Price | Value | Of their stake | Filing |
|---|---|---|---|---|---|---|---|
| May 20 | Samsara Biocapital, L.p. Large holder | Bought | 244,300 | $4.83 | $1.18M | 1.9% | Form 4 |
| Mar 20 | Brett R Hagen Chief Accounting Officer | SoldNo plan | 1,915 | $6.72 | 13K | 100% | Form 4 |
| Dec 18, 2025 | Samsara Opportunity Fund, L.p. Large holder | Bought | 479,847 | $10.42 | $5M | 3.8% | Form 4 |
| Mar 26, 2025 | Brett R Hagen Chief Accounting Officer | SoldNo plan | 907 | $8.97 | 8K | 32% | Form 4 |
| Feb 21, 2025 | Vikas Sinha See Remarks | SoldNo plan | 303 | $10.08 | 3K | <0.1% | Form 4 |
| Feb 21, 2025 | Brett R Hagen Chief Accounting Officer | SoldNo plan | 96 | $10.08 | $968 | 3.3% | Form 4 |
| Feb 21, 2025 | Edward Miller General Counsel | SoldNo plan | 106 | $10.08 | 1K | 0.5% | Form 4 |
| Jan 23, 2025 | Edward Miller General Counsel | SoldNo plan 2 parts | 52 | $9.50 average | $494 | 0.2% | Form 4 |
| Jan 23, 2025 | Brett R Hagen Chief Accounting Officer | SoldNo plan 2 parts | 36 | $9.50 average | $342 | 1.2% | Form 4 |
| Jan 23, 2025 | Vikas Sinha See Remarks | SoldNo plan 2 parts | 129 | $9.50 average | 1K | <0.1% | Form 4 |
| Jan 10, 2025 | Edward Miller General Counsel | SoldNo plan | 409 | $0.44 | $180 | <0.1% | Form 4 |
| Jan 10, 2025 | Brett R Hagen Chief Accounting Officer | SoldNo plan | 332 | $0.44 | $146 | 0.5% | Form 4 |
| Jan 10, 2025 | Vikas Sinha See Remarks | SoldNo plan | 979 | $0.44 | $431 | <0.1% | Form 4 |
- May 20Samsara Biocapital, L.p.Large holder · bought 244,300 at $4.83$1.18M1.9% of stake
- Mar 20No planBrett R HagenChief Accounting Officer · sold 1,915 at $6.7213K100% of stake
- Dec 18, 2025Samsara Opportunity Fund, L.p.Large holder · bought 479,847 at $10.42$5M3.8% of stake
- Mar 26, 2025No planBrett R HagenChief Accounting Officer · sold 907 at $8.978K32% of stake
- Feb 21, 2025No planVikas SinhaSee Remarks · sold 303 at $10.083K<0.1% of stake
- Feb 21, 2025No planBrett R HagenChief Accounting Officer · sold 96 at $10.08$9683.3% of stake
- Feb 21, 2025No planEdward MillerGeneral Counsel · sold 106 at $10.081K0.5% of stake
- Jan 23, 2025No planEdward MillerGeneral Counsel · sold 52 at avg $9.50$4940.2% of stake
- Jan 23, 2025No planBrett R HagenChief Accounting Officer · sold 36 at avg $9.50$3421.2% of stake
- Jan 23, 2025No planVikas SinhaSee Remarks · sold 129 at avg $9.501K<0.1% of stake
- Jan 10, 2025No planEdward MillerGeneral Counsel · sold 409 at $0.44$180<0.1% of stake
- Jan 10, 2025No planBrett R HagenChief Accounting Officer · sold 332 at $0.44$1460.5% of stake
- Jan 10, 2025No planVikas SinhaSee Remarks · sold 979 at $0.44$431<0.1% of stake
Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with KLRS
Spot a number that looks wrong? Check it in KLRS's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing KLRS
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.